SCHEMBL7863124

SCHEMBL7863124

O=C(c1ccc(Cl)c(Cl)c1)N1CC(CN2CCC(c3ccc(F)cc3)CC2)C(c2ccoc2)C1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 19/20 0.60
HSD11B1 P28845 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7870867 0.91 CCR5 (0.72) CCR5
SCHEMBL7835196 0.88 CCR5 (0.71) CCR5
SCHEMBL7871072 0.85 CCR5 (0.61) CCR5
SCHEMBL7871243 0.85 CCR5 (0.54) CCR5HSD11B1
SCHEMBL7871240 0.85 CCR5 (0.54) CCR5HSD11B1
SCHEMBL7871194 0.84 CCR5 (0.61) CCR5
SCHEMBL8082673 0.83 CCR5 (0.69) CCR5
SCHEMBL7687718 0.82 CCR5 (0.50) CCR5HSD11B1
SCHEMBL7681785 0.82 CCR5 (0.50) CCR5HSD11B1
SCHEMBL7837039 0.82 CCR5 (0.79) CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6303593-B1 FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS MERCK & CO., INC. 2001-10-16 US claimed
US-6303593-B1 FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS MERCK & CO., INC. 2001-10-16 US disclosed
WO-2000051608-A1 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 2000-09-08 WO disclosed